In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the form of amyloid fibrils.
AstraZeneca announced that the European Commission has granted Marketing Authorisation to Zinforo(ceftaroline fosamil), a new intravenous cephalosporin antibiotic, for the...
For over a century, acute 'post-streptococcal glomerulonephritis' (APSGN) was the prototypical form of bacterial infection-associated glomerulonephritis, typically occurring after resolution of infection and a distinct infection-free latent period.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Emblaveo, intended for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia and infections due to aerobic Gram-negative organisms in patients with limited treatment options.
Objective: To assess critically oritavancin, a second-generation lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.
This guideline, relating to the provision of a percutaneously placed enteral tube feeding service, is focused upon a specific area of nutrition provision that has not been previously targeted.
Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults (see sections 4.4 and 5.1): • Complicated skin and soft tissue infections (cSSTI) • Community-acquired pneumonia (CAP) Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Basilea Pharmaceutica Ltd announced today positive topline results for the phase III ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB).
Levofloxacin 5 mg/ml Solution for Infusion is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1): • Community-acquired pneumonia, • Complicated skin and soft tissue infections/Complicated skin and skin structure infections. In Complicated skin and soft tissue infections/Complicated skin and skin structure infections, Levofloxacin 5 mg/ml Solution for Infusion should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. • Acute pyelonephritis and complicated urinary tract infections (see section 4.4); • Chronic bacterial prostatitis; • Inhalation Anthrax: post-exposure prophylaxis and curative treatment (see section 4.4). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Clarithromycin film-coated tablets are indicated for the treatment of the following bacterial infections, when caused by clarithromycin-susceptible bacteria (see section 4.4 and 5.1). • Bacterial pharyngitis • Mild to moderate community acquired pneumonia • Acute bacterial sinusitis (adequately diagnosed) • Acute exacerbation of chronic bronchitis • Skin infections and soft tissue infections of mild to moderate severity, • In appropriate combination with antibacterial therapeutic regimens and an appropriate ulcer healing agent for the eradication of Helicobacter pylori in patients with Helicobacter pylori associated ulcers (see section 4.2). Consideration should be given to official guidance on the appropriate use of antibacterial agents.